|  |  |  |  |
| --- | --- | --- | --- |
| Порядковый номер ссылки | Авторы, название публикации и источника, где она опубликована, выходные данные | ФИО, название публикации и источника на английском языке | Полный интернет-адрес (URL) цитируемой статьи или ее doi |
| 1 | Altenburg A.F., Rimmelzwaan G.F., de Vries R.D. Virus-specific T cells as correlate of (cross-) protective immunity against influenza. Vaccine, 2015, Vol.33, pp.500–506. | - | [10.1016/j.vaccine.2014.11.054] |
| 2 | Ameghi A. Protective immunity against homologous and heterologous influenza virus lethal challenge by immunization with new recombinant chimeric HA2-M2e fusion protein in balb/c mice. Viral. Immunol., 2016, Vol. 29, pp. 228-234. | - | [10.1089/vim.2015.0050] |
| 3 | Bates J.T. Mucosal adjuvant activity of flagellin in aged mice. Mech. Ageing Dev., 2008, Vol. 129, pp. 271–281. | - | [10.1016/j.mad.2008.01.009] |
| 4 | Bessa J., Schmitz N., Hinton H.J. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol., 2008, Vol. 38, N 1, pp. 114–126. | - | [10.1002/eji.200636959] |
| 5 | Bommakanti G. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. U S A., 2010, Vol. 107, pp. 13701-1376. | - | [10.1073/pnas.1007465107] |
| 6 | Cho K.J., Schepens B., Seok J.H., Kim S., Roose K., Lee J.H. Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. J. Virol., 2015 Vol. 89 pp. 3700-3711. | - | [10.1128/JVI.02576-14] |
| 7 | Cunningham A.F., Khan M., Ball J., Toellner K.M., Serre K., Mohr E. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol., 2004; Vol. 34, pp. 2986–2995. | - | [10.1002/eji.200425403] |
| 8 | Delaney K.N., Phipps J.P., Johnson J.B., Mizel S.B. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol., 2010, Vol.23, pp.201–210. | - | [10.1089/vim.2009.0107] |
| 9 | Deng L., Kim J.R., Chang T.Z., Zhang H., Mohan T., Champion J.A., Wang B-Z. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza a virus challenge. Virology, 2017, Vol. 509, pp. 82–89. | - | [10.1016/j.virol.2017.06.001] |
| 10 | Denis J., Acosta-Ramirez E., Zhao Y. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine, 2008, Vol. 26, N 27-28, pp. 3395–3403. | - | [10.1016/j.vaccine.2008.04.052] |
| 11 | Ekiert D.C. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science, 2011, Vol. 333, pp. 843-850. | - | [10.1126/science.1204839] |
| 12 | El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol., 2011, Vol.186, pp. 1022–1031. | - | [10.4049/jimmunol.0902147] |
| 13 | Eliasson D.G., Omokanye A., SchoЁn K. M2e tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Mucosal Immunol., 2017, Vol.11, pp.273-289. | - | [10.1038/mi.2017.14] |
| 14 | Feng J. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J., 2006, Vol. 3, pp.102. | - | [10.1186/1743-422X-3-102] |
| 15 | Gong X. Conserved stem fragment from H3 influenza hemagglutinin elicits cross-clade neutralizing antibodies through stalk-targeted blocking of conformational change during membrane fusion. Immunol. Lett., 2016, Vol. 172, pp. 11–20. | - | [10.1016/j.imlet.2016.02.006] |
| 16 | Guo Y., He L., Song N., Li P., Sun S., Zhao G., Tai W., Jiang S., Du L., Zhou Y. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection. Microbes Infect., 2017, Vol. 19, pp. 641-647. | - | [10.1016/j.micinf.2017.08.010] |
| 17 | Hashimoto Y., Moki T., Takizawa T., Shiratsuchi A., Nakanishi Y. Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol., 2007, Vol.178, pp.2448–2457. | - | http://www.jimmunol.org/content/178/4/2448.long |
| 18 | Hazenbos W.L., Gessner J.E., Hofhuis F.M. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity, 1996 Vol.5, pp. 181–188. | - | https://www.ncbi.nlm.nih.gov/pubmed/?term=Impaired+IgG-dependent+anaphylaxis+and+Arthus+reaction+in+Fc+gamma+RIII+(CD16)+deficient+mice. |
| 19 | Hillaire M.L., Osterhaus A.D., Rimmelzwaan G.F. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol., 2011, 2011:939860. | - | [10.1155/2011/939860] |
| 20 | Honko, A.N. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun., 2006, Vol. 74, pp. 1113–1120. | - | [10.1128/IAI.74.2.1113-1120.2006] |
| 21 | Huleatt J.W. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine, 2008. Vol. 26, pp. 201–214. | - | [10.1016/j.vaccine.2007.10.062] |
| 22 | Ingrole R.S., Tao W., Tripathy J.N., Gill H.S. Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen. Nano. Life., 2014, Vol. 4, N 2, 1450004. | - | [10.1142/s1793984414500044] |
| 23 | Ionescu R.M., Przysiecki C.T., Liang X. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J. Pharm. Sci., 2006, Vol. 95, N 1, pp. 70–79. | - | [10.1002/jps.20493] |
| 24 | Jegerlehner A. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol., 2004, Vol. 172, pp. 5598-5605. | - | http://www.jimmunol.org/content/172/9/5598.long |
| 25 | Khanna M. Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. BioMed. Res. Int., 2014, 2014:546274. | - | [10.1155/2014/546274] |
| 26 | Kim M-C. Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus. Molecular Therapy, 2013, Vol. 21, pp. 485–492. | - | [10.1038/mt.2012.246] |
| 27 | Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, Vol. 227, pp. 680–685. | - | https://www.ncbi.nlm.nih.gov/pubmed/5432063 |
| 28 | Liu G. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine, 2012, Vol. 30, pp. 6833–6838. | - | [10.1016/j.vaccine.2012.09.013] |
| 29 | Liu W., Peng Z., Liu Z. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine, 2004, Vol. 23, N 3, pp. 366–371. | - | [10.1016/j.vaccine.2004.05.028] |
| 30 | Mozdzanovska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virology J., 2007, 4: 118. | - | [10.1186/1743-422X-4-118] |
| 31 | Neirynck S., Deroo T., Saelens X., Vanlandschoot P. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med., 1999, Vol. 5, N 10, pp. 1157–1163. | - | [10.1038/13484] |
| 32 | Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin G subclasses activity through selective Fc receptor binding. Science, 2005, Vol. 310, pp. 1510–1512. | - | [10.1126/science.1118948] |
| 33 | Nimmerjahn F., Ravetch J.V. Fc-gamma receptors: old friends and new family members. Immunity, 2006, Vol.24, pp.19–28. | - | [10.1016/j.immuni.2005.11.010] |
| 34 | Schotsaert M. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert. Rev. Vaccines., 2009, Vol. 8. pp. 499–508. | - | [10.1586/erv.09.6] |
| 35 | Slepushkin V.A., Katz J.M., Black R.A. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine, 1995, Vol. 13, N 15, pp. 1399–1402. | - | https://www.sciencedirect.com/science/article/pii/0264410X9592777Y?via%3Dihub |
| 36 | Stepanova L.A. A Fusion Protein Based on the Second Subunit of Hemagglutinin of Influenza A/H2N2 Viruses Provides Cross Immunity. Acta Naturae., 2016, Vol. 8, pp. 116-126. | - | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947995/ |
| 37 | Stepanova L.A. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. PLoS One, 2015, Vol. 10, e0119520. | - | [10.1371/journal.pone.0119520] |
| 38 | Stepanova L.A., Mardanova E.S., Shuklina M.A. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes. Journal of Biomedical Science, 2018, 25:33 | - | [10.1186/s12929-018-0433-5] |
| 39 | Taylor D.N. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine, 2011, Vol. 29, pp. 4897-4902. | - | [10.1016/j.vaccine.2011.05.001] |
| 40 | Tsybalova L.M. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e. Vaccine, 2015, Vol. 33, pp. 3398-3406. | - | [10.1016/j.vaccine.2015.04.073] |
| 41 | Turley C.B. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine, 2011, Vol. 29, pp. 5145-5152. | - | [10.1016/j.vaccine.2011.05.041] |
| 42 | Wang T.T. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PloS Pathog., 2010, Vol. 6, e1000796. | - | [10.1371/journal.ppat.1000796] |
| 43 | Wang T.T. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U S A., 2010, Vol. 107, pp. 18979-18984. | - | [10.1073/pnas.1013387107] |
| 44 | WHO. Human infection with avian influenza A(H7N9) virus – China. Disease outbreak news. 26 October 2017. | - | www.who.int/entity/csr/don/26-october-2017-ah7n9-china/en |
| 45 | Wrammert, J. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med., 2011, Vol. 208, pp. 181-193. | - | [10.1084/jem.20101352] |
| 46 | Wu F., Huang J.H., Yuan X.Y. Characterization of immunity induced by M2e of influenza virus. Vaccine, 2007, Vol. 25, N 52, pp. 8868–8873. | - | [10.1016/j.vaccine.2007.09.056] |
| 47 | Zhang H., Wang L., Compans R.W., Wang B.Z. Universal influenza vaccines, a dream to be realized soon. Viruses, 2014, Vol. 6, pp. 1974–91. | - | [10.3390/v6051974] |
| 48 | Zhou L., Ren R., Yang L., Bao C., Wu J., Wang D. Sudden increase in human infection with avian influenza A(H7N9) virus in China, Semptember-December 2016. Western Pac Surveill Response J., 2017; Vol. 8, pp. 6-14. | - | [10.5365/WPSAR.2017.8.1.001] |